Doctors argue that some drug companies are charging too much for their cancer drugs, to the detriment of patients.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
The H7N9 virus is deadly to humans but does not present symptoms in birds, which makes it more difficult to control.
The impending Supreme Court ruling on gene patents is creating uncertainty in the molecular diagnostics sector.
A startup called Catabasis is developing drugs that hit diseases at multiple targets.
An easy-to-use EEG cap could expand the number of ways to interact with your mobile devices.
Your genome may not change, but your microbiome will.
Despite breakthroughs in technology and medicine, there's still a lot of work ahead for understanding and using the human genome.
Mice tap into their own neural reward circuits with the help of a new optogenetics device.